Full Text View
Tabular View
Study Results
Related Studies
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
This study has been terminated.
Study NCT00387426   Information provided by National Cancer Institute (NCI)

First Received on October 12, 2006.   Last Updated on April 30, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Undifferentiated Leukemia
Chronic Myelomonocytic Leukemia
Mast Cell Leukemia
Primary Myelofibrosis
Prolymphocytic Leukemia
Refractory Hairy Cell Leukemia
Secondary Acute Myeloid Leukemia
Untreated Hairy Cell Leukemia
Additional conditions recognized in this trial
Blast Crisis
Congenital Abnormalities
Leukemia
Leukemia, Hairy Cell
Leukemia, Large Granular Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Mast-Cell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myeloid, Acute
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Leukemia, Myeloid, Chronic-Phase
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Prolymphocytic
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Bone Marrow Diseases
Cell Transformation, Neoplastic
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Leukemia, T-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Mastocytosis
Mastocytosis, Systemic
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
sunitinib malate
Additional drug interventions recognized in this trial
Sunitinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services